Drug developers Zogenix Inc. and Desitin Pharmaceuticals GmbH said that they received approval in Germany for the needle-free version of the migraine treatment sumatriptan.
The companies received approval for Sumavel DosePro, which is administered beneath the skin without a needle. It was recently approved in Denmark.
In 2008 San Diego-based Zogenix granted Germany-based Desitin exclusive rights to develop and sell Sumavel in Europe. The companies plan to launch the drug in Germany and Denmark in early 2011.
Sumavel DosePro is marketed in the U.S. by Astellas.
Date: January 6, 2010
Source: Associated Press
Filed Under: Drug Discovery
